Aytu Biopharma (AYTU) Net Cash Flow (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Net Cash Flow data on file, last reported at -$3.3 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$3.3 million, down 48.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.5 million (up 638.25% YoY), and the FY2025 annual result was $10.9 million, up 467.44% from the prior year.
• Net Cash Flow fell to -$3.3 million in Q1 2026 per AYTU's latest filing, from -$2.6 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $12.8 million in Q2 2025 and troughed at -$8.3 million in Q2 2022.
• A 5-year average of -$503647.1 and a median of -$310000.0 in 2023 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 5094.72% in 2025 and fell as far as 1063.2% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$4.4 million in 2022, then soared by 90.05% to -$435000.0 in 2023, then jumped by 166.67% to $290000.0 in 2024, then slumped by 998.28% to -$2.6 million in 2025, then declined by 27.06% to -$3.3 million in 2026.
• Business Quant data shows AYTU's Net Cash Flow at -$3.3 million in Q1 2026, -$2.6 million in Q4 2025, and $1.7 million in Q3 2025.